vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Meridian Corp (MRBK). Click either name above to swap in a different company.
Meridian Corp is the larger business by last-quarter revenue ($34.2M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). Meridian Corp runs the higher net margin — 428.0% vs -0.8%, a 428.8% gap on every dollar of revenue. On growth, Meridian Corp posted the faster year-over-year revenue change (5.1% vs -25.7%). Meridian Corp produced more free cash flow last quarter ($22.6M vs $-15.8M). Over the past eight quarters, Meridian Corp's revenue compounded faster (18.0% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Meridian Audio is a consumer audio and home theatre equipment manufacturer based in the United Kingdom. Bob Stuart and Allen Boothroyd founded the company in 1977 under the name Boothroyd-Stuart. In 1985 the company released a CD player under the brand name, Meridian. The company also created the lossless compression format Meridian Lossless Packing in 1998 and the lossy Master Quality Authenticated (MQA) format in 2014.
CTMX vs MRBK — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $34.2M |
| Net Profit | $-154.0K | $7.2M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 27.2% |
| Net Margin | -0.8% | 428.0% |
| Revenue YoY | -25.7% | 5.1% |
| Net Profit YoY | 97.6% | 28.3% |
| EPS (diluted) | — | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $34.2M | ||
| Q3 25 | — | $33.1M | ||
| Q2 25 | $18.7M | $32.4M | ||
| Q1 25 | $50.9M | $27.1M | ||
| Q4 24 | $38.1M | $32.6M | ||
| Q3 24 | $33.4M | $29.1M | ||
| Q2 24 | $25.1M | $26.1M | ||
| Q1 24 | $41.5M | $24.6M |
| Q4 25 | — | $7.2M | ||
| Q3 25 | — | $6.7M | ||
| Q2 25 | $-154.0K | $5.6M | ||
| Q1 25 | $23.5M | $2.4M | ||
| Q4 24 | $18.9M | $5.6M | ||
| Q3 24 | $5.7M | $4.7M | ||
| Q2 24 | $-6.5M | $3.3M | ||
| Q1 24 | $13.8M | $2.7M |
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 26.2% | ||
| Q2 25 | -6.9% | 22.5% | ||
| Q1 25 | 44.4% | 11.6% | ||
| Q4 24 | 46.4% | 23.3% | ||
| Q3 24 | 12.3% | 21.5% | ||
| Q2 24 | -33.7% | 16.8% | ||
| Q1 24 | 28.1% | 14.4% |
| Q4 25 | — | 428.0% | ||
| Q3 25 | — | 20.1% | ||
| Q2 25 | -0.8% | 17.2% | ||
| Q1 25 | 46.2% | 8.9% | ||
| Q4 24 | 49.6% | 366.8% | ||
| Q3 24 | 17.2% | 16.3% | ||
| Q2 24 | -26.0% | 12.7% | ||
| Q1 24 | 33.3% | 10.9% |
| Q4 25 | — | $0.61 | ||
| Q3 25 | — | $0.58 | ||
| Q2 25 | — | $0.49 | ||
| Q1 25 | — | $0.21 | ||
| Q4 24 | — | $0.49 | ||
| Q3 24 | — | $0.42 | ||
| Q2 24 | — | $0.30 | ||
| Q1 24 | — | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $199.7M |
| Total Assets | $175.1M | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $199.7M | ||
| Q3 25 | — | $188.0M | ||
| Q2 25 | $119.9M | $178.0M | ||
| Q1 25 | $25.0M | $173.6M | ||
| Q4 24 | $-456.0K | $171.5M | ||
| Q3 24 | $-23.5M | $167.4M | ||
| Q2 24 | $-31.2M | $162.4M | ||
| Q1 24 | $-31.7M | $159.9M |
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $175.1M | $2.5B | ||
| Q1 25 | $98.5M | $2.5B | ||
| Q4 24 | $120.5M | $2.4B | ||
| Q3 24 | $139.0M | $2.4B | ||
| Q2 24 | $159.2M | $2.4B | ||
| Q1 24 | $184.7M | $2.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $24.3M |
| Free Cash FlowOCF − Capex | $-15.8M | $22.6M |
| FCF MarginFCF / Revenue | -84.6% | 65.9% |
| Capex IntensityCapex / Revenue | 0.1% | 5.1% |
| Cash ConversionOCF / Net Profit | — | 3.38× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $51.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.3M | ||
| Q3 25 | — | $24.4M | ||
| Q2 25 | $-15.8M | $-12.0M | ||
| Q1 25 | $-21.0M | $18.1M | ||
| Q4 24 | $-19.9M | $9.6M | ||
| Q3 24 | $-20.7M | $31.2M | ||
| Q2 24 | $-19.5M | $-19.2M | ||
| Q1 24 | $-26.0M | $-1.7M |
| Q4 25 | — | $22.6M | ||
| Q3 25 | — | $24.0M | ||
| Q2 25 | $-15.8M | $-12.7M | ||
| Q1 25 | $-21.2M | $17.9M | ||
| Q4 24 | $-20.0M | $9.0M | ||
| Q3 24 | $-20.7M | $29.5M | ||
| Q2 24 | $-19.6M | $-19.3M | ||
| Q1 24 | $-26.2M | $-3.6M |
| Q4 25 | — | 65.9% | ||
| Q3 25 | — | 72.4% | ||
| Q2 25 | -84.6% | -39.1% | ||
| Q1 25 | -41.6% | 65.9% | ||
| Q4 24 | -52.5% | 27.7% | ||
| Q3 24 | -62.1% | 101.4% | ||
| Q2 24 | -78.2% | -73.8% | ||
| Q1 24 | -63.1% | -14.7% |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 0.1% | 1.9% | ||
| Q1 25 | 0.2% | 1.0% | ||
| Q4 24 | 0.2% | 1.7% | ||
| Q3 24 | 0.1% | 6.0% | ||
| Q2 24 | 0.4% | 0.2% | ||
| Q1 24 | 0.3% | 7.8% |
| Q4 25 | — | 3.38× | ||
| Q3 25 | — | 3.66× | ||
| Q2 25 | — | -2.15× | ||
| Q1 25 | -0.89× | 7.55× | ||
| Q4 24 | -1.05× | 1.71× | ||
| Q3 24 | -3.61× | 6.58× | ||
| Q2 24 | — | -5.78× | ||
| Q1 24 | -1.89× | -0.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
MRBK
Segment breakdown not available.
